Fabry Disease Clinical Trial Pipeline Major pharmaceutical companies are working to advance the pipeline space and unlock the future growth ...

GC Biopharma, a South Korean biopharmaceutical company, announced on Feb. 10th that it presented development updates on its LSD (lysosomal storage disorder) pipelines at the WORLD Symposium 2025, held ...

AceLink is advancing a small-molecule treatment option for Fabry disease that could provide a more convenient alternative to ...

Fabry disease is an X-linked lysosomal storage disorder caused by a deficiency of the enzyme α-galactosidase A (GLA), which leads to complex multisystemic involvement, with the majority of patients ...

Like we explained, legumes are high in oligosaccharides, so they really have the capacity to trigger some tooting across the ...

Sangamo Therapeutics (NASDAQ:SGMO) reported positive updated data from a Phase 1/2 study of its gene therapy candidate isaralgagene civaparvovec, or ST-920, in the treatment of Fabry disease. The ...

RICHMOND, Calif. - Sangamo Therapeutics, Inc. (NASDAQ: SGMO), a genomic medicine company with a market capitalization of $263 million, has announced promising updated results from its Phase 1/2 STAAR ...

According to research, taking the supplement can help enhance digestion and easy gut problems like bloating, gas and stomach ...

These supplements often contain enzymes such as amylase, lipase, and protease. Some also include lactase and alpha-galactosidase, which the body does not naturally produce, even in healthy ...

These supplements often include enzymes such as amylase, lipase, and protease. Some also feature lactase and alpha-galactosidase, which the body does not produce, even in healthy individuals ...

Oral Platform Presentation: Pompe Disease: Abstract Title: Miglustat: A first-in-class enzyme stabilizer for late-onset Pompe disease Abstract Title: Clinically important improvements in 6-minute walk ...